Enliven Therapeutics (ELVN) Competitors $20.36 -0.32 (-1.55%) Closing price 04:00 PM EasternExtended Trading$20.36 0.00 (-0.02%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELVN vs. TGTX, CYTK, AAPG, KRYS, ACAD, ADMA, TLX, PCVX, PTCT, and LNTHShould you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include TG Therapeutics (TGTX), Cytokinetics (CYTK), Ascentage Pharma Group International (AAPG), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), Telix Pharmaceuticals (TLX), Vaxcyte (PCVX), PTC Therapeutics (PTCT), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Enliven Therapeutics vs. Its Competitors TG Therapeutics Cytokinetics Ascentage Pharma Group International Krystal Biotech ACADIA Pharmaceuticals ADMA Biologics Telix Pharmaceuticals Vaxcyte PTC Therapeutics Lantheus Enliven Therapeutics (NASDAQ:ELVN) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation. Which has stronger earnings & valuation, ELVN or TGTX? TG Therapeutics has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$89.02M-$2.00-10.18TG Therapeutics$454.07M10.12$23.38M$0.3778.27 Is ELVN or TGTX more profitable? TG Therapeutics has a net margin of 13.31% compared to Enliven Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 26.05% beat Enliven Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -29.15% -27.88% TG Therapeutics 13.31%26.05%9.58% Do analysts recommend ELVN or TGTX? Enliven Therapeutics currently has a consensus target price of $41.20, indicating a potential upside of 102.36%. TG Therapeutics has a consensus target price of $46.25, indicating a potential upside of 59.70%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Enliven Therapeutics is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do institutionals and insiders believe in ELVN or TGTX? 95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 25.9% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, ELVN or TGTX? Enliven Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500. Does the media prefer ELVN or TGTX? In the previous week, TG Therapeutics had 1 more articles in the media than Enliven Therapeutics. MarketBeat recorded 7 mentions for TG Therapeutics and 6 mentions for Enliven Therapeutics. TG Therapeutics' average media sentiment score of 1.52 beat Enliven Therapeutics' score of 0.22 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryTG Therapeutics beats Enliven Therapeutics on 10 of the 15 factors compared between the two stocks. Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELVN vs. The Competition Export to ExcelMetricEnliven TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.21B$2.79B$5.76B$9.84BDividend YieldN/A1.68%3.95%4.03%P/E Ratio-10.1822.8231.3126.60Price / SalesN/A742.70461.61121.39Price / CashN/A177.7737.7659.36Price / Book2.476.1810.026.67Net Income-$89.02M$32.94M$3.27B$265.59M7 Day Performance2.62%0.99%3.17%3.42%1 Month Performance-1.50%1.69%4.34%1.09%1 Year Performance-9.11%11.44%44.12%23.84% Enliven Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELVNEnliven Therapeutics2.768 of 5 stars$20.36-1.5%$41.20+102.4%-8.3%$1.21BN/A-10.1850TGTXTG Therapeutics4.4007 of 5 stars$28.53-3.1%$46.25+62.1%+23.6%$4.67B$329M77.11290Positive NewsCYTKCytokinetics3.7387 of 5 stars$37.01-3.5%$71.58+93.4%-32.3%$4.59B$85.74M-7.26250News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$43.48-9.2%N/AN/A$4.45B$134.35M0.00600Gap UpHigh Trading VolumeKRYSKrystal Biotech4.7119 of 5 stars$146.77-2.5%$210.38+43.3%-25.5%$4.36B$290.52M29.83210ACADACADIA Pharmaceuticals4.0332 of 5 stars$25.32-1.6%$28.88+14.0%+68.7%$4.34B$957.80M19.04510ADMAADMA Biologics4.3421 of 5 stars$17.01-4.4%$27.67+62.6%-0.6%$4.25B$426.45M19.78530News CoveragePositive NewsTLXTelix PharmaceuticalsN/A$12.20-2.2%$22.33+83.1%N/A$4.22B$516.72M0.00N/AAnalyst ForecastAnalyst RevisionGap DownPCVXVaxcyte2.389 of 5 stars$30.45-5.7%$136.50+348.3%-61.2%$4.19BN/A-7.41160Positive NewsPTCTPTC Therapeutics4.3263 of 5 stars$49.30-2.5%$69.15+40.3%+40.9%$4.02B$806.78M7.071,410LNTHLantheus4.7624 of 5 stars$56.16-3.5%$105.50+87.9%-47.9%$3.96B$1.53B14.94700Analyst Revision Related Companies and Tools Related Companies TG Therapeutics Competitors Cytokinetics Competitors Ascentage Pharma Group International Competitors Krystal Biotech Competitors ACADIA Pharmaceuticals Competitors ADMA Biologics Competitors Telix Pharmaceuticals Competitors Vaxcyte Competitors PTC Therapeutics Competitors Lantheus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELVN) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access